The Body PRO Covers: The 8th Conference on Retroviruses and Opportunistic Infections

Pharmacology of Antiviral Chemotherapeutic Agents

February 5, 2001

  • Pharmacologic Characteristics of Efavirenz (EFV) and Nelfinavir (NFV) Associated with Virologic Response in HIV-Infected Children (Slide Session 259)
    Authored by C. V. Fletcher, T. Fenton, C. Powell, P. L. Anderson, R. C. Brundage, S. A. Spector, and S. E. Starr
    View the original abstract

Results from PACTG 382 was presented by Courtney Fletcher. In that study, HIV-infected children who were NNRTI- and PI-naive were started on efavirenz and nelfinavir and one new NRTI. The primary results were published in the New England Journal of Medicine in 1999. This analysis involved the pharmacology focus whereby 50 study subjects had intensive pharmacokinetic (pK) studies performed at weeks two and six. The study was set up so that the pK results would be available quickly so that the area under the curve could be measured and doses adjusted after the week two results were available in order to hit a target level. Those data resulted in a change in the efavirenz doses in 50% of the children (usually increased) and an increase in 20% of the nelfinavir doses. Analysis of the virologic response demonstrated that children with higher AUCs for efavirenz and nelfinavir at week two had a more rapid decrease in plasma RNA levels. Those results seem to support efforts to optimize dosing of anti-HIV drugs soon after initiating therapy.

Previous | Next

This article was provided by TheBodyPRO. It is a part of the publication The 8th Conference on Retroviruses and Opportunistic Infections.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.